deltatrials
Completed PHASE1/PHASE2 INTERVENTIONAL 6-arm NCT03222492

Brentuximab Vedotin for Systemic Sclerosis (BRAVOS)

Evaluation of Brentuximab Vedotin for Diffuse Cutaneous Systemic Sclerosis BRAVOS: A Phase 1/2 Multicenter Randomized, Double Blinded, Safety Study (ITN075AI)

Sponsor: Immune Tolerance Network (ITN)

Conditions Diffuse Cutaneous Systemic Sclerosis Scleroderma dcSSc
Interventions Brentuximab Vedotin Placebo
Updated 26 times since 2017 Last updated: Apr 22, 2024 Started: Sep 20, 2017 Primary completion: Apr 10, 2023 Completion: Apr 10, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Diffuse Cutaneous Systemic Sclerosis and Scleroderma and is currently completed. Immune Tolerance Network (ITN) leads this study, which shows 26 recorded versions since 2017 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Aug 2017 – ~Oct 2017 · 2 months · monthly snapshot~Oct 2017 – ~Dec 2017 · 2 months · monthly snapshot~Dec 2017 – ~Feb 2018 · 2 months · monthly snapshot~Feb 2018 – ~Jun 2018 · 4 months · monthly snapshot~Jun 2018 – ~Oct 2018 · 4 months · monthly snapshot~Oct 2018 – ~Sep 2019 · 11 months · monthly snapshot~Sep 2019 – ~Nov 2019 · 2 months · monthly snapshot~Nov 2019 – ~Dec 2019 · 30 days · monthly snapshot~Dec 2019 – ~Aug 2020 · 8 months · monthly snapshot~Aug 2020 – ~Nov 2020 · 3 months · monthly snapshot~Nov 2020 – ~Dec 2020 · 30 days · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Apr 2021 · 59 days · monthly snapshot~Apr 2021 – ~May 2021 · 30 days · monthly snapshot~May 2021 – ~Jun 2022 · 13 months · monthly snapshot~Jun 2022 – ~Mar 2023 · 9 months · monthly snapshot~Mar 2023 – ~Oct 2023 · 7 months · monthly snapshot~Oct 2023 – ~Dec 2023 · 2 months · monthly snapshot~Dec 2023 – ~Jun 2024 · 6 months · monthly snapshot~Jun 2024 – ~Jul 2024 · 30 days · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Oct 2024 · 30 days · monthly snapshot~Oct 2024 – ~Jun 2025 · 8 months · monthly snapshot~Jun 2025 – ~Sep 2025 · 3 months · monthly snapshot~Sep 2025 – present · 11 months · monthly snapshot

Change History

26 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE1/PHASE2

  2. Jun 2025 — Sep 2025 [monthly]

    Completed PHASE1/PHASE2

  3. Oct 2024 — Jun 2025 [monthly]

    Completed PHASE1/PHASE2

  4. Sep 2024 — Oct 2024 [monthly]

    Completed PHASE1/PHASE2

  5. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

▶ Show 21 earlier versions

  1. Jun 2024 — Jul 2024 [monthly]

    Completed PHASE1_PHASE2

  2. Dec 2023 — Jun 2024 [monthly]

    Completed PHASE1_PHASE2

  3. Oct 2023 — Dec 2023 [monthly]

    Completed PHASE1_PHASE2

    Status: Active Not Recruiting → Completed

  4. Mar 2023 — Oct 2023 [monthly]

    Active Not Recruiting PHASE1_PHASE2

    Status: Recruiting → Active Not Recruiting

  5. Jun 2022 — Mar 2023 [monthly]

    Recruiting PHASE1_PHASE2

  6. May 2021 — Jun 2022 [monthly]

    Recruiting PHASE1_PHASE2

  7. Apr 2021 — May 2021 [monthly]

    Recruiting PHASE1_PHASE2

  8. Feb 2021 — Apr 2021 [monthly]

    Recruiting PHASE1_PHASE2

  9. Jan 2021 — Feb 2021 [monthly]

    Recruiting PHASE1_PHASE2

  10. Dec 2020 — Jan 2021 [monthly]

    Recruiting PHASE1_PHASE2

  11. Nov 2020 — Dec 2020 [monthly]

    Recruiting PHASE1_PHASE2

  12. Aug 2020 — Nov 2020 [monthly]

    Recruiting PHASE1_PHASE2

  13. Dec 2019 — Aug 2020 [monthly]

    Recruiting PHASE1_PHASE2

  14. Nov 2019 — Dec 2019 [monthly]

    Recruiting PHASE1_PHASE2

  15. Sep 2019 — Nov 2019 [monthly]

    Recruiting PHASE1_PHASE2

  16. Oct 2018 — Sep 2019 [monthly]

    Recruiting PHASE1_PHASE2

  17. Jun 2018 — Oct 2018 [monthly]

    Recruiting PHASE1_PHASE2

  18. Feb 2018 — Jun 2018 [monthly]

    Recruiting PHASE1_PHASE2

  19. Dec 2017 — Feb 2018 [monthly]

    Recruiting PHASE1_PHASE2

  20. Oct 2017 — Dec 2017 [monthly]

    Recruiting PHASE1_PHASE2

    Status: Not Yet Recruiting → Recruiting

  21. Aug 2017 — Oct 2017 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Immune Tolerance Network (ITN)
  • National Institute of Allergy and Infectious Diseases (NIAID)
  • PPD Development, LP
  • Rho Federal Systems Division, Inc.
  • Seagen Inc.
Data source: National Institute of Allergy and Infectious Diseases (NIAID)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations